Tools to Guide Treatment Decisions in Breast Cancer

Mark Pegram, MD, and Lee Schwartzberg, MD, FACP, have a discussion on the management of early-stage hormone-receptor-positive breast cancer and the tools available to help inform treatment decisions.

EP. 1: The Evolution of Early-Stage HR+ Breast Cancer Management

August 5th 2022

Lee Schwartzberg, MD, FACP, and Mark Pegram, MD, discuss how the management of early-stage HR+ breast cancer has changed over time.

EP. 2: Measuring Ki-67 Levels to Inform HR+ Breast Cancer Treatment

August 5th 2022

Lee Schwartzberg, MD, FACP, explains how Ki-67 is measured and used to inform management strategies for HR+ breast cancer at his clinical practice.

EP. 3: Updated Guidelines for the Management of HR+ Breast Cancer

August 12th 2022

Experts highlight some important and surprising updates in the ASCO guidelines for the management of HR+ breast cancer.

EP. 4: Recurrence Patterns in Early-Stage HR+ Breast Cancer

August 12th 2022

Drs Mark Pegram and Lee Schwartzberg examine late recurrence patterns in patients with HR+ breast cancer.

EP. 5: Tools to Guide Treatment Decision-Making in HR+ Breast Cancer

August 19th 2022

Mark Pegram, MD, details the role of biomarkers in predicting recurrences in patients with HR+ breast cancer.

EP. 6: Ordering Additional Multigene Assays for Patients with HR+ Breast Cancer

August 19th 2022

Drs Schwartzberg and Pegram debate the value of having patients undergo more than 1 multigene assay to predict their risk of recurrence.

EP. 7: Data on Extended Adjuvant Endocrine Therapy in HR+ Breast Cancer

August 26th 2022

Lee Schwartzberg, MD, FACP, explains the IDEAL study and data on the benefits of extended adjuvant endocrine therapy in HR+ breast cancer.

EP. 8: Biomarkers for Selection of Extended Endocrine Therapy in HR+ Breast Cancer

August 26th 2022

Experts discuss biomarkers used to determine if a patient with HR+ breast cancer will benefit from extended endocrine therapy.

EP. 9: Clinical and Practical Implications of the Breast Cancer Index

September 7th 2022

A review of when to use the Breast Cancer Index for patients with HR+ breast cancer when deciding on endocrine therapy duration.

EP. 10: Future Directions in HR+ Breast Cancer Management

September 7th 2022

Lee Schwartzberg, MD, FACP, and Mark Pegram, MD, highlight exciting prognostic technology on the horizon for HR+ breast cancer.